Hypervariable polymorphism in the APOC3 gene

Bhattacharya, Shoumo; Wilson, Teresa; Wojciechowski, A.P.; Volpe, C.P.; Scott, James

doi:10.1093/nar/19.17.4799

Cited by 14 publications

(8 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In these cases DNA was extracted using the methods described by Sarkar (1995). The LOH analysis using the highly informative mononucleotide repeat microsatellite marker APOC3 (Bhattacharya et al, 1991) was performed either in Oulu or in the research centre from where the tissue material was collected. Polymerase chain reaction (PCR) was performed mainly as described previously (Bhattacharya et al, 1991), with some slight modifications, e.g.…”

Section: Methodsmentioning

confidence: 99%

European multicenter study on LOH of APOC3 at 11q23 in 766 breast cancer patients: relation to clinical variables

et al. 1999

View full text Add to dashboard Cite

Loss of heterozygosity (LOH) for a specific chromosome region may indicate the presence of a tumour suppressor gene (TSG). Studies on tumour LOH have therefore been helpful to identify many TSGs (Bièche and Lidereau, 1995). High incidences of LOH of the 11q22-qter chromosome region have been seen in breast cancer (Hampton et al, 1994;Gudmundsson et al, 1995;Winqvist et al, 1995;Kerangueven et al, 1997;Laake et al, 1997) and also in several other human malignancies (Herbst et al, 1995;Rasio et al, 1995;Gabra et al, 1996;Hui et al, 1996). In addition, it has been shown that chromosome 11 can suppress tumorigenicity when transferred to breast cancer (Negrini et al, 1994;Phillips et al, 1996) and melanoma cell lines (Robertson et al, 1996).The distal half of chromosome 11q contains several genes indicated to be involved in tumorigenesis; e.g. ATM (the ataxia telangiectasia disorder gene at 11q23.1), DDX10 (a putative RNA helicase gene at 11q23.1), MLL1 (a gene at 11q23 frequently rearranged in acute leukaemia), LOH11CR2A (a potential tumour suppressor gene at 11q23) and CHEK1 (a gene at 11q24 encoding a protein kinase required for the DNA damage checkpoint function) (Ziemin-van der Poel et al, 1991;Savitsky et al, 1995Savitsky et al, , 1996Furnari et al, 1997;Monaco et al, 1997;Sanchez et al, 1997).LOH at 11q23 has been reported in association with poor postmetastatic survival in breast cancer (Winqvist et al, 1995). The crucial region of LOH seemed to map between loci D11S35 (11q22) and APOC3 (apolipoprotein C-3 at 11q23) (Hampton et al, 1994), in a chromosomal segment of less than 17 Mb (Arai et al, 1996). In the initial study of a Finnish breast cancer cohort, APOC3 appeared to be the most suitable marker for more careful examinations of the clinical effects of LOH of the 11q23 chromosomal region. Therefore, in the present European multicentrestudy, we analysed tumour and normal tissue pairs of 766 primary breast cancer patients from 11 countries to investigate the association between LOH at the APOC3 locus and clinical variables in greater detail. MATERIALS AND METHODSAltogether 766 primary tumour and normal tissue pairs from breast cancer patients were collected for the LOH analysis. The Summary High frequencies of loss of heterozygosity (LOH) in chromosome 11q22-qter have been observed in various malignancies, including breast cancer. Previous studies on breast carcinomas by Winqvist et al (Cancer Res 55: 2660-2664) have indicated that a survival factor gene is located in band 11q23, and that the highly informative microsatellite polymorphism at the APOC3 locus would be a suitable tool to perform more extensive LOH studies. In this European multicentre study, we have examined the occurrence of APOC3 LOH and evaluated the effect of LOH of this chromosomal subregion on the clinical behaviour of the disease in a cohort of 766 breast cancer patients in more detail. LOH for APOC3 was found in 42% of the studied tumours, but it was not found to be significantly associated with any of the studied clinical variables,...

show abstract

Section: Methodsmentioning

confidence: 99%

European multicenter study on LOH of APOC3 at 11q23 in 766 breast cancer patients: relation to clinical variables

et al. 1999

View full text Add to dashboard Cite

show abstract

“…Gene frequencies of the apo CIII microsatellite were determined from the genotype of the 66 unrelated Caucasians. This polymorphic region was amplified by PCR using previously reported oligonucleotides (Bhattacharya et al 1991). Prior to PCR analysis the forward primer was end-labeled using [γ-33 P] ATP (DuPont NEN) and T4 polynucleotide kinase (Sambrook et al 1989).…”

Section: Genotypingmentioning

confidence: 99%

“…In recent years, RFLPs have been supplanted by highly polymorphic microsatellite regions. A very informative microsatellite, which consists of 24 alleles, has been identified within the apo CIII gene (Bhattacharya et al 1991).…”

Section: Introductionmentioning

confidence: 99%

Linkage of the apo CIII microsatellite with isolated low high-density lipoprotein cholesterol

1998

View full text Add to dashboard Cite

To evaluate whether a highly polymorphic microsatellite region within intron 3 of the apolipoprotein (apo) CIII gene is linked to the isolated low HDL-C phenotype, we studied eight unrelated probands (mean HDL-C = 10+/-5 mg/dl) and 157 biological family members. After PCR amplification of genomic DNA and denaturing polyacrylamide gel electrophoresis, 26 alleles were identified in this microsatellite including 9 alleles heretofore unreported. Quantitative sib-pair linkage analysis demonstrated strong evidence of linkage between the isolated low HDL-C phenotype and the apo CIII microsatellite region (P = 0.007). The microsatellite was also linked to apo AI (P = 0.001), the primary apolipoprotein of HDL-C. Therefore, this highly polymorphic microsatellite region is a potentially important marker in the genetic evaluation of the isolated low HDL-C phenotype.

show abstract

“…DNA sequences flanking polymorphic microsatellite loci on chromosome 11 were taken from published studies. These included dinucleotide polymorphisms within the WTI (19), PYGM (20), and INT-2 (21) genes and at the DJJS901, D11S902, D11S968 (22), and DJIS35 (23) loci, a tetranucleotide repeat within the THgene (24), a hypervariable polymorphism within the APOC3 gene (25), and a variable number tandem repeat (VNTR)-like polymorphism at the DJS533 locus (26). The locations of these polymorphisms are depicted in boxes in Fig.…”

mentioning

confidence: 99%

Loss of heterozygosity in cervical carcinoma: subchromosomal localization of a putative tumor-suppressor gene to chromosome 11q22-q24.

Hampton

Penny

Baergen

et al. 1994

Proc. Natl. Acad. Sci. U.S.A.

120

View full text Add to dashboard Cite

show abstract

Hypervariable polymorphism in the APOC3 gene

Cited by 14 publications

References 3 publications

European multicenter study on LOH of APOC3 at 11q23 in 766 breast cancer patients: relation to clinical variables

European multicenter study on LOH of APOC3 at 11q23 in 766 breast cancer patients: relation to clinical variables

Linkage of the apo CIII microsatellite with isolated low high-density lipoprotein cholesterol

Loss of heterozygosity in cervical carcinoma: subchromosomal localization of a putative tumor-suppressor gene to chromosome 11q22-q24.

Contact Info

Product

Resources

About